Abstract
Royal jelly is a food for queen and larvae honeybees. 10-Hydroxy-trans-2-decenoic acid (10H2DA; “royal jelly acid”) is the principal lipid component in royal jelly. Several pharmacological activities of 10H2DA have been reported: anti-tumor, anti-biotic, immunomodulatory, estrogenic and neurogenic. We recently revealed an inhibitory effect of 10H2DA in innate immune signals. Despite appreciable advances in studies on innate immune signals after the identification of Toll-like receptors as innate immune receptors, few studies have reported the effect of 10H2DA on innate immune signals. In this review, we focus on recent advances in the evaluation of the biological activities of 10H2DA (especially immunomodulatory activities). We also discuss the molecular mechanisms underpinning these biological activities, which could lead to new therapeutic targets for the treatment of immune disorders.
Keywords: Fatty acids, immune disorders, immunomodulator, innate immunity, royal jelly, Toll-like receptors, 10-Hydroxy-trans-2-decenoic acid (10H2DA; “royal jelly acid”), propolis, ω-hydroxy lipids, royal jelly protein (MRJP)1, nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), innate and adaptive immunity.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Royal Jelly Acid, 10-Hydroxy-trans-2-Decenoic Acid, as a Modulator of the Innate Immune Responses
Volume: 12 Issue: 4
Author(s): Tsuyoshi Sugiyama, Keita Takahashi and Hiroshi Mori
Affiliation:
Keywords: Fatty acids, immune disorders, immunomodulator, innate immunity, royal jelly, Toll-like receptors, 10-Hydroxy-trans-2-decenoic acid (10H2DA; “royal jelly acid”), propolis, ω-hydroxy lipids, royal jelly protein (MRJP)1, nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), innate and adaptive immunity.
Abstract: Royal jelly is a food for queen and larvae honeybees. 10-Hydroxy-trans-2-decenoic acid (10H2DA; “royal jelly acid”) is the principal lipid component in royal jelly. Several pharmacological activities of 10H2DA have been reported: anti-tumor, anti-biotic, immunomodulatory, estrogenic and neurogenic. We recently revealed an inhibitory effect of 10H2DA in innate immune signals. Despite appreciable advances in studies on innate immune signals after the identification of Toll-like receptors as innate immune receptors, few studies have reported the effect of 10H2DA on innate immune signals. In this review, we focus on recent advances in the evaluation of the biological activities of 10H2DA (especially immunomodulatory activities). We also discuss the molecular mechanisms underpinning these biological activities, which could lead to new therapeutic targets for the treatment of immune disorders.
Export Options
About this article
Cite this article as:
Sugiyama Tsuyoshi, Takahashi Keita and Mori Hiroshi, Royal Jelly Acid, 10-Hydroxy-trans-2-Decenoic Acid, as a Modulator of the Innate Immune Responses, Endocrine, Metabolic & Immune Disorders - Drug Targets 2012; 12 (4) . https://dx.doi.org/10.2174/187153012803832530
DOI https://dx.doi.org/10.2174/187153012803832530 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Innovations in Antibody-Mediated, Targeted Particulate Nanotechnology and Implications for Advanced Visualisation and Drug Delivery
Current Nanoscience Mechanism of Cancer Drug Resistance and the Involvement of Noncoding RNAs
Current Medicinal Chemistry Epidermal Growth Factor Receptor Inhibitors: A New Prospective in the Treatment of Lung Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Reduced-Intensity Transplantation in the Treatment of Haematological Malignancies: Current Status and Future-Prospects
Current Stem Cell Research & Therapy Prodrugs of Non-steroidal Anti-inflammatory Drugs (NSAIDs): A Long March Towards Synthesis of Safer NSAIDs
Mini-Reviews in Medicinal Chemistry Cancer and Phase II Drug-Metabolizing Enzymes
Current Drug Metabolism Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Dicoumarol: A Drug which Hits at Least Two Very Different Targets in Vitamin K Metabolism
Current Drug Targets Application of Stem Cell Therapy During the Treatment of HIV/AIDS and Duchenne Muscular Dystrophy
Current Stem Cell Research & Therapy The Role of Nucleoside Transport in the Antineoplastic Activity of Purine Nucleoside Chemotherapeutic Agents
Current Cancer Therapy Reviews Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics Double-Faced Role of Human Mesenchymal Stem Cells and their Role/Challenges in Cancer Therapy
Current Stem Cell Research & Therapy Sumoylation in Cellular Senescence and Aging
Current Molecular Medicine Glycerophospholipid Synthesis as a Novel Drug Target Against Cancer
Current Molecular Pharmacology Emerging Role of Wnt/Beta-Catenin Signalling Pathways in Cancer Progression and Role of Small Molecule Tankyrase Inhibitors in Combating Multistage Cancers
Current Cancer Therapy Reviews Large Granular Lymphocyte (LGL) Leukemia: Pathobiology, Diagnosis and Treatment
Current Cancer Therapy Reviews Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Current Drug Discovery Technologies Regulatory Approaches to Nonclinical Reproductive Toxicity Testing of Anti-Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Application of Artificial Neural Networks for the Prediction of Antitumor Activity of a Series of Acridinone Derivatives
Medicinal Chemistry Composite Lymphomas: A Challenging Entity
Current Cancer Therapy Reviews